Analyst Ratings For IDEXX Laboratories

In the latest quarter, 4 analysts provided ratings for IDEXX Laboratories IDXX, showcasing a mix of bullish and bearish perspectives.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $564.0, a high estimate of $596.00, and a low estimate of $510.00. Observing a downward trend, the current average is 5.74% lower than the prior average price target of $598.33.

Understanding Analyst Ratings: A Comprehensive Breakdown

A comprehensive examination of how financial experts perceive IDEXX Laboratories is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IDEXX Laboratories. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IDEXX Laboratories compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of IDEXX Laboratories's stock. This examination reveals shifts in analysts' expectations over time.

For valuable insights into IDEXX Laboratories's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on IDEXX Laboratories analyst ratings.

Get to Know IDEXX Laboratories Better

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

A Deep Dive into IDEXX Laboratories's Financials

Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.

Revenue Growth: IDEXX Laboratories displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 7.1%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: IDEXX Laboratories's net margin is impressive, surpassing industry averages. With a net margin of 24.44%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): IDEXX Laboratories's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.43% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): IDEXX Laboratories's ROA excels beyond industry benchmarks, reaching 7.12%. This signifies efficient management of assets and strong financial health.

Debt Management: IDEXX Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.68.

Analyst Ratings: What Are They?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.